Condition: Advanced Solid Tumor · Sponsor: BeOne Medicines
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Study Director · 8778285568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| University of Alabama At Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer At Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Next Houston | Houston, Texas, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
| Blacktown Cancer and Haematology Centre | Blacktown, New South Wales, Australia | Recruiting |
| Genesiscare St Leonards | St Leonards, New South Wales, Australia | Recruiting |
| Icon Cancer Centre Wesley | Auchenflower, Queensland, Australia | Recruiting |
| Cabrini Hospital Malvern | Malvern, Victoria, Australia | Recruiting |
| Peter Maccallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| One Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07226349